focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biomedica Share News (OXB)

Share Price Information for Oxford Biomedica (OXB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 331.50
Bid: 330.00
Ask: 333.50
Change: 0.00 (0.00%)
Spread: 3.50 (1.061%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 331.50
OXB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET OPEN: Stocks jump and pound heads towards USD1.42 mark

Tue, 18th May 2021 08:45

(Alliance News) - After a strong session for stock markets in Asia, the FTSE 100 raced out the blocks on Tuesday morning, even as the pound continued to climb following a better-than-expected UK jobs print.

The FTSE 100 index was up 56.73 points, or 0.8%, at 7,089.58 early Tuesday. The mid-cap FTSE 250 index was up 178.23 points, or 0.8%, at 22,392.37. The AIM All-Share index was up 0.3% at 1,237.98.

The Cboe UK 100 index was up 0.7% at 707.04. The Cboe 250 was up 0.7% at 20,131.69, and the Cboe Small Companies down 0.1% at 14,910.04.

In mainland Europe, the CAC 40 in Paris was up 0.5%, while the DAX 30 in Frankfurt rose 0.7% early Tuesday.

In Asia on Tuesday, the Japanese Nikkei 225 index ended up 2.1%. In China, the Shanghai Composite closed up 0.3%, while the Hang Seng index in Hong Kong was up 1.3% in late trade. The S&P/ASX 200 in Sydney ended up 0.6%.

"Nothing has materially changed overnight, but with the Covid-19 nerves steadied from yesterday, regional fast-money investors look bored with selling and have reversed course today," said Jeffrey Halley, senior market analyst for Asia Pacific at Oanda.

With shares up 2.6% in opening dealings, Fresnillo was the top performer in London's blue-chip FTSE 100 index on Tuesday.

The precious metals miner was tracking the price of gold higher, quoted at USD1,870.36 early Tuesday, up from USD1,865.60 on Monday.

Brent oil also rose, trading at USD70.12 a barrel, up from USD69.24 late Monday. BP shares were 1.4% higher in early trade, while Royal Dutch Shell 'A' and 'B' shares rose 1.2% and 1.3% respectively.

At the bottom of the FTSE 100 was Vodafone, down 7.4% as it posted a slip in full-year earnings.

Revenue for the financial year to March 31 was EUR43.81 billion, down 2.6% from EUR44.97 billion the year before. Pretax profit jumped to EUR4.40 billion, however, from just EUR795 million the year before, after financing costs fell to EUR1.03 billion from EUR3.55 billion.

However, adjusted earnings before interest, tax, depreciation and amortisation fell 3.3% - or declining 1.2% on an organic basis - to EUR14.39 billion from EUR14.88 billion.

Vodafone kept its dividend for the year steady at 9.0 cents.

"Vodafone's results are slightly behind the market's expectations, with lockdown in Europe still partly to blame. Although not a company to set the heart racing with excitement, Vodafone can continue to grow slowly and has a very attractive and well covered dividend, which is currently yielding 5.7%," said Richard Flood, investment manager at Brewin Dolphin.

At the top of the FTSE 250 was Micro Focus International, jumping 10% as it guided to interim revenue ahead of market forecasts.

The enterprise software firm expects to report revenue of around USD1.4 billion for the six months to the end of April, ahead of market expectations and marking a decline of around 5% on a constant currency basis year-on-year. An adjusted Ebitda margin of around 36% for the period is also ahead of market expectations.

"Whilst there is a great deal to do, we are encouraged by our progress and remain committed to delivering revenue stabilisation and sustainable cash flow generation for our shareholders," said Micro Focus Chief Executive Stephen Murdoch.

Oxford Biomedica rose 7.4%. It raised its guidance after pharmaceutical firm AstraZeneca committed to an increase in the number of Covid-19 vaccines needed from the gene and cell therapy company in the second half of 2021.

The two signed an 18-month supply agreement in September under a three-year master supply and development agreement for the large-scale commercial manufacture of the Oxford-AstraZeneca vaccine.

As a result of Astra's commitment, Oxford Biomedica raised its revenue guidance for expected cumulative revenue from Astra by the end of 2021 to in excess of GBP100 million, from in excess of GBP50 million previously, and as such expects "significant growth" in operating Ebitda this year.

As equities in London started Tuesday on the front foot, the pound was also higher after some upbeat UK jobs news.

The unemployment rate was 4.8% for the three months to March, easing from 4.9% in the three months to February. Consensus, according to FXStreet, had seen the March reading holding steady at 4.9%.

"The latest figures suggest that the jobs market has been broadly stable in recent months, with some early signs of recovery," the ONS said.

This coincides with the easing of lockdown restrictions in the UK. In March, schools in England reopened, followed by the lifting of shutters in April for outdoor hospitality, such as beer gardens, alongside non-essential retail and hairdressers.

The number of payroll employees increased for a fifth consecutive month in April, though does still remain 772,000 below pre-pandemic levels. The largest falls in jobs since February 2020 have been in the hospitality sector, among those aged under 25 years, and those living in London.

Sterling eyed the USD1.42 mark after the data, quoted at USD1.4196 early Tuesday compared to USD1.4119 at the London equities close on Monday.

The US dollar was lower against other major currency pairings.

Against the yen, the dollar slipped to JPY108.99 early Tuesday versus JPY109.20 late Monday. The euro changed hands at USD1.2197, higher than USD1.2146.

In the economic calendar on Tuesday, besides UK jobs, there are eurozone employment and GDP at 1000 BST and US housing starts at 1330 BST.

By Lucy Heming; lucyheming@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
16 Apr 2021 09:49

BROKER RATINGS: RBC upgrades WH Smith and downgrades Dixons Carphone

BROKER RATINGS: RBC upgrades WH Smith and downgrades Dixons Carphone

Read more
15 Apr 2021 09:02

Oxford Biomedica swings to EBITDA profit

(Sharecast News) - Oxford Biomedica reported a 37% improvement in total revenues in its preliminary results on Thursday, to £87.7m.

Read more
15 Apr 2021 09:00

Oxford BioMedica annual revenue leaps on AstraZeneca vaccine deal

Oxford BioMedica annual revenue leaps on AstraZeneca vaccine deal

Read more
8 Apr 2021 16:05

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
6 Apr 2021 08:19

Oxford Biomedica signs viral vectors pact with Boehringer Ingelheim

Oxford Biomedica signs viral vectors pact with Boehringer Ingelheim

Read more
6 Apr 2021 08:08

Oxford Biomedica strikes three-year deal with Boehringer Ingelheim

(Sharecast News) - Gene and cell therapy company Oxford Biomedica has signed a new three-year development and supply agreement with Boehringer Ingelheim, it announced on Tuesday, for the manufacture and supply of various types of viral vectors.

Read more
6 Apr 2021 07:53

LONDON MARKET PRE-OPEN: Returns in store for BP shareholders

LONDON MARKET PRE-OPEN: Returns in store for BP shareholders

Read more
21 Mar 2021 20:57

EU rebuffs UK calls to ship AstraZeneca COVID vaccines from Europe

By Francesco GuarascioBRUSSELS, March 21 (Reuters) - The European Union is rebuffing British government calls to ship AstraZeneca COVID-19 vaccines produced in a factory in the Netherlands, an EU official said on Sunday.Former EU member Britain ha...

Read more
19 Mar 2021 10:29

Sanofi to terminate haemophilia development pact with Oxford Biomedica

Sanofi to terminate haemophilia development pact with Oxford Biomedica

Read more
19 Mar 2021 07:50

Oxford Biomedica says Sanofi pulling out of haemophilia project

(Sharecast News) - Oxford Biomedica said that Sanofi's decision to terminate collaboration on a haemophilia treatment would have a "negligible" impact on revenue.

Read more
3 Feb 2021 13:56

IN BRIEF: Oxford Biomedica Adds Genetics Professor To Non-Exec Team

IN BRIEF: Oxford Biomedica Adds Genetics Professor To Non-Exec Team

Read more
29 Jan 2021 09:11

UPDATE 1-EU holds out for more after AstraZeneca offered 8 mln extra COVID-19 shots

* Astra had committed to at least 80 mln shots in Q1* EU funded two UK plants under deal with Astra - sources* Astra says UK has priority for doses produced there (Adds detail, background)By Francesco Guarascio and Sabine SieboldBRUSSELS, Jan 29 (Re...

Read more
18 Jan 2021 17:18

IN BRIEF: Oxford Biomedica's Facility In Oxford Now Formally Opened

IN BRIEF: Oxford Biomedica's Facility In Oxford Now Formally Opened

Read more
8 Jan 2021 09:40

UK BROKER RATINGS SUMMARY: Shore Says Buy Hargreaves; UBS Cuts Next

UK BROKER RATINGS SUMMARY: Shore Says Buy Hargreaves; UBS Cuts Next

Read more
8 Dec 2020 12:31

UK's initial AstraZeneca shots will come from Europe, taskforce says

By Alistair SmoutLONDON, Dec 8 (Reuters) - Britain's initial doses of the COVID-19 vaccine candidate developed by AstraZeneca and Oxford University will come from Europe rather than a domestic supply chain, the country's Vaccine Taskforce said.The...

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.